Key Opinion Leader (KOL) consensus for actinic keratosis management in Italy: The AKTUAL Workshop

Giornale Italiano di Dermatologia e Venereologia

Volumn 148, Issue 5, 2013, Pages 515-524

  Peserico, A ^a   Neri, L ^b,c   Calzavara Pinton, P ^d   Catricala C ^e   Pellacani, G ^f   Peris, K ^g   Pimpinelli, N ^h  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF L'AQUILA   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; SUNSCREEN;

ACTINIC KERATOSIS; APPLICATION SITE CRUSTING; APPLICATION SITE ERYTHEMA; APPLICATION SITE FLAKING; APPLICATION SITE INFECTION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; APPLICATION SITE SCALING; APPLICATION SITE SWELLING; CARBON DIOXIDE LASER; CLINICAL DECISION MAKING; CLINICAL FEATURE; CONFERENCE PAPER; CRYOSURGERY; CURETTAGE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; ERBIUM YAG LASER; HISTOPATHOLOGY; HUMAN; ITALY; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; SKIN CARCINOMA; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84888879589     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (90)

1. Schmitt AR, Bordeaux JS. Actinic neoplasia syndrome and an update on the epidemiology of basal cell carcinoma, squamous cell carcinoma, and actinic keratosis. Current Dermatology Reports 2013;2:42-7.
2. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses, I: methods and descriptive results of the South Wales skin cancer study. Br J Cancer 1996;74:1302-7. (Pubitemid 26360124)
3. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000;142:1154-9. (Pubitemid 30418302)
4. Vitasa BC, Taylor HR, Strickland PT, Rosenthal FS, West S, Abbey H et al. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer 1990;65:2811-7. (Pubitemid 20179563)
5. Marks R, Ponsford MW, Selwood TS, Goodman G, Mason G. Non-melanotic skin cancer and solar keratoses in Victoria. Med J Aust 1983;2:619-22. (Pubitemid 14197506)
6. Stockfleth E, Kerl H. Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006;16:599-606.
7. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115:2523-30.
8. Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol 2013;68(1 Suppl 1):S20-7.
9. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratosis. BJD 2007;156:222-30.
10. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H;European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008;18:651-9.
11. Rossi R, Calzavara-Pinton PG, Giannetti A, Peserico A, Santucci M, Vena GA et al. Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol 2009;144:713-23.
12. Stockfleth E, Terhorst D, Braathen L, Cerio R, Ferrandiz C, Giannetti A, Guideline Subcommittee of the European Dermatology Forum. Guidelines on actinic keratosis: an update. Eur J Dermatol 2006;16:599-606.
13. Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol 2003;139:66-70. (Pubitemid 36091577)
14. Dubreuilh WA. Des hyperkeratosis circonscrites. Ann Dermatol Venereol 1896;27:1158-64.
15. Rosen T, Lebwohl, MG. Prevalence and awareness of actinic keratosis: Barriers and opportunities. J Am Acad Dermatol 2013;68(1 Suppl 1):S2-9.
16. Deltondo JA, Helm KF Actinic keratosis: precancer, squamous cell carcinoma, or marker of field cancerization? G Ital Dermatol Venereol 2009;144:441-4.
17. Marks R. Who benefits from calling a solar keratosis a squamous cell carcinoma? Br J Dermatol 2006;155:23-6. (Pubitemid 43876388)
18. Engman MF. Precancerous conditions of the skin. J Lab Clin Med 1915;1:31-9.
19. Jorizzo JL, Carney PS, Ko WT, Robins P, Weinkle SH, Werschler WP. Treatment options in the management of actinic keratosis. Cutis 2004;74(Suppl 6):S9-17.
20. Epstein E. Quantifying actinic keratosis: assessing the evidence. Am J Clin Dermatol 2004;5:141-4. (Pubitemid 38901542)
21. Freeman RG, Barr RJ, Elder DE. What is the boundary that separates a thick actinic keratosis from a thin squamous-cell carcinoma? Am J Dermatopathol 1984;6:301-6.
22. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J et al. Imiquimod 5% cream for the treatment of actinic keratosis: resuits from two phase III, randomized double-blind, parallel-group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21.
23. Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma:a clinical, histopathologic correlation. Dermatol Surg 2006;32:1261-5.
24. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006;55:9-22.
25. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H et al. Actinic keratosis is an early in situ squamous cell carcinoma:a proposal for reclassification. Br J Dermatol 2007;156 (Suppl 3):S8-12.
26. Guenthner ST, Hurwitz RM, Buckel LJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathologic correlation. J Am Acad Dermatol 1999;41(3 Pt 1):443-8. (Pubitemid 29418513)
27. Terushkin V, Braga JC, Dusza SW, Scope A, Busam K, Marghoob AA et al. Agreement on the clinical diagnosis and management of cutaneous squamous neoplasms. Dermatol Surg 2010;36:1514-20.
28. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses:Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115:2523-30.
29. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42(1 Pt 2):23-4.
30. Jorizzo J, Stewart D, Bucko A, Davis SA, Espy P, Hino P et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002;70:335-9. (Pubitemid 41757441)
31. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502. (Pubitemid 35315741)
32. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses 1. Methods and descriptive results of the South Wales skin cancer study. Br J Cancer 1996;74:1302-7. (Pubitemid 26360124)
33. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986;115:649-55. (Pubitemid 17181888)
34. Venna SS, Lee D, Stadecker MJ, Rogers GS. Clinical recognition of actinic keratoses in a high-risk population, how good are we? Arch Dermatol Arch Dermatol 2005;141:507-9. (Pubitemid 40547411)
35. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J et al. Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773-6.
36. Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma:a spectrum of disease progression. Arch Dermatol 2010;146:288-93.
37. Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol 2013;68(1 Suppl 1):S10-9.
38. Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol 1997;36:650-3. (Pubitemid 27164509)
39. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Klowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998;37:677-81. (Pubitemid 28428318)
40. Ashton KJ, Weinstein SR, Maguire DJ, Griffiths LR. Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization. Arch Dermatol 2003;139:876-82. (Pubitemid 36898922)
41. Whited JD, Homer RD, Hall RP, Simel DL. The influence of history on interobserver agreement for diagnosing actinic keratoses and malignant skin lesions. J Am Acad Dermatol 1995;33:603-7.
42. Huerta-Brogeras M, Olmos O, Borbujo J, Hernández- Núñez A, Castaño E, Romero-Maté A et al. Validation of dermoscopy as a real-time noninvasive diagnostic imaging technique for actinic keratosis. Arch Dermatol 2012;148:1159-64.
43. Peris K, Micantonio T, Piccolo D, Concetta M. Dermoscopic features of actinic keratosis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2007;5:970-5.
44. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007;33:1099-101. (Pubitemid 47339694)
45. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatology 2002;146:810-5. (Pubitemid 34539190)
46. Foote JA, Harris RB, Giuliano AR, Roe DJ, Moon TE, Cartmel B et al. Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults. Int J Cancer 2001;95:7-11.
47. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002;160:251-8.
48. Mitropoulos P, Norman R. Occupational nonsolar risk factors of squamous cell carcinoma of the skin:a population-based case-controlled study. Dermatol Online J 2005;11:5.
49. Schwartz RA, Bridges TM, Butani AK, Ehrlich A. Actinic keratosis: an occupational and environmental disorder. J Eur Acad Dermatol Venereol 2008;22:606-15. (Pubitemid 351541058)
50. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988;1:795-7. (Pubitemid 18094914)
51. Dodson JM, De Spain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatments patient-oriented perspective. Arch Dermatol 1991;127:1029-31.
52. Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol 2013;68(Suppl 1):S28-38.
53. Peris K, Neri L, Calzavara-Pinton P, Catricalà C, Pellacani G, Pimpinelli N et al. Physicians Opinions and Clinical Practice Patterns for AK management in Italy. GIDEV [In press].
54. Thai KE, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004;43:687-92. (Pubitemid 39276301)
55. Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008;158:994-9. (Pubitemid 351521450)
56. Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate- photodynamic therapy and cryotherapy in subjects with actinic keratoses:a multicentre, randomized controlled study. Br J Dermatol 2006;155:1029-36. (Pubitemid 44564515)
57. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomized study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157(Suppl 2):S34-40.
58. Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol 2002;146:18-25. (Pubitemid 34158404)
59. Scola N, Terras S, Georgas D, Othlinghaus N, Matip R, Pantelaki I et al. A randomized, half-side comparative study of aminolaevulinate photodynamic therapy vs. CO2 laser ablation in immunocompetent patients with multiple actinic keratoses. Br J Dermatol 2012;167:1366-73.
60. Goette DK. Topical chemotherapy with 5-fluorouracil. J Am Acad Dermatol 1981;4:633-49.
61. Jury CS, Ramraka-Jones VS, Gudi V, Herd RM. A randomized trial of topical 5% 5-fluorouracil in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol 2005;153:808-10. (Pubitemid 41415910)
62. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis:Critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005;9:209-14. (Pubitemid 44265792)
63. Meijer BU, de Waard-van der Spek FB. Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix cream). Contact Dermatitis 2007;57:58-60. (Pubitemid 46944430)
64. Yentzer B, Hick J, Williams L, Inabinet R, Wilson R, Camacho FT et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009;145:203-5.
65. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006;126:1251-5. (Pubitemid 43997904)
66. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratosis on the head. Br J Dermatol 2007;157(Suppl 2):41-6. (Pubitemid 350179629)
67. Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, McRae S et al. Vehicle-controlled, doubleblind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for AK. Update on actinic keratosis in clinical trial experience with Imiquimod. Br J Dermatol 2007;157(Suppl 2):S32-33.
68. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of Imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007;157:133-41. (Pubitemid 46934262)
69. Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008;159:205-10. (Pubitemid 351874499)
70. Fayter D, Corbett M, Heirs M, Fox D, Eastwood A. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess 2010;14.
71. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007;56:125-43. (Pubitemid 44969292)
72. Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008;158:994-9. (Pubitemid 351521450)
73. Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis:a prospective, randomized study. J Am Acad Dermatol 2002;47:258-62.
74. Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis:a prospective, randomized study. J Dermatolog Treat 2003;14:99-106. (Pubitemid 36648700)
75. Fecker LF, Stockfleth E, Braun FK, Rodust PM, Schwarz C, Köhler A et al. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatmentwith diclofenac/hyaluronic acid correlates with downregulation of c-FLIP:J Invest Dermatol 2010;130:2098-109.
76. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1 alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17:2115-7.
77. Martin GM, Stockfleth E. Diclofenac sodium 3% gel for the management of actinic keratosis:10+ years of cumulative evidence of efficacy and safety. J Drugs Dermatol 2012;11:600-8.
78. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004;3:401-7.
79. Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stoekfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010;20:482-90.
80. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. NEJM 2012;366:1010-9.
81. Peris K, Neri L, Fargnoli MC, Pellacani G. Physicians' concerns toward prescription adherence and treatment effectiveness in the clinical management of actinic keratosis. G Ital Dermatol Venereol [In press].
82. Ondo AL, Padilla RS, Miedler JD, Cockerell CJ, Kerner JD, Steiner RL et al. Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study. Dermatol Surg 2012;38:1469-76.
83. Held L, Eigentler TK, Leiter U, Garbe C, Berneburg MJ. Effective combination of photodynamic therapy and imiquimod 5% cream in the treatment of actinic keratoses: three cases. Biomed Res Int 2013;2013:102698.
84. Gilbert DJ. Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J Drugs Dermatol 2005;4:161-5.
85. Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol 2009;8:35-9.
86. Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol 2007;6:778-81.
87. Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratosis. Clin Exp Dermatol 2009;34:33-5.
88. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses:a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol 2006;5:133-9.
89. Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient-assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratosis. Eur J Dermatol 2012;22:370-4.
90. Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011;165:1101-8.